CoChat
Sign Up
Cited by 841

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Epigenetic modulators, modifiers and mediators in cancer aetiology and progression

Feinberg, Andrew P., Koldobskiy, Michael A., Göndör, Anita·2016·Nature Reviews Genetics
DOI 10.1038/nrg.2016.13PMC PMC4888057
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrg.2016.13

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Research works printed but not linked: 233

  1. Feinberg, A. P., Ohlsson, R. & Henikoff, S. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 7, 21–33 (2006). This is the model suggesting that some genes are epigenetically disrupted at the earliest stages of malignancies, even before mutations, causing altered differentiation throughout tumour evolution; the current Review revisits this model. · DOI
  2. Versteege, I. et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394, 203–206 (1998). · DOI
  3. Lee, R. S. et al. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J. Clin. Invest. 122, 2983–2988 (2012). · DOI
  4. Zhang, J. et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 481, 329–334 (2012). · DOI
  5. Pugh, T. J. et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 488, 106–110 (2012). · DOI · Paper page
  6. Hovestadt, V. et al. Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. Nature 510, 537–541 (2014). · DOI
  7. Shen, H. & Laird, P. W. Interplay between the cancer genome and epigenome. Cell 153, 38–55 (2013). · DOI
  8. Plass, C. et al. Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat. Rev. Genet. 14, 765–780 (2013). · DOI
  9. Yan, X. J. et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat. Genet. 43, 309–315 (2011). · DOI
  10. Couronne, L., Bastard, C. & Bernard, O. A. TET2 and DNMT3A mutations in human T-cell lymphoma. N. Engl. J. Med. 366, 95–96 (2012). · DOI
  11. Grossmann, V. et al. The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL. Genes Chromosomes Cancer 52, 410–422 (2013). · DOI
  12. Ribeiro, A. F. et al. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood 119, 5824–5831 (2012). · DOI
  13. Challen, G. A. et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat. Genet. 44, 23–31 (2012). · DOI · Paper page
  14. Challen, G. A. et al. Dnmt3a and Dnmt3b have overlapping and distinct functions in hematopoietic stem cells. Cell Stem Cell 15, 350–364 (2014). · DOI · Paper page
  15. Mayle, A. et al. Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation. Blood 125, 629–638 (2015). · DOI · Paper page
  16. Quivoron, C. et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20, 25–38 (2011). · DOI · Paper page
  17. Abdel-Wahab, O. et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114, 144–147 (2009). · DOI · Paper page
  18. Langemeijer, S. M. et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat. Genet. 41, 838–842 (2009). · DOI
  19. Chou, W. C. et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood 118, 3803–3810 (2011). · DOI
  20. Papaemmanuil, E. et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122, 3616–3627 (2013). · DOI · Paper page
  21. Itzykson, R. et al. Clonal architecture of chronic myelomonocytic leukemias. Blood 121, 2186–2198 (2013). · DOI
  22. Busque, L. et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat. Genet. 44, 1179–1181 (2012). · DOI · Paper page
  23. Moran-Crusio, K. et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20, 11–24 (2011). · DOI · Paper page
  24. Madzo, J. et al. Hydroxymethylation at gene regulatory regions directs stem/early progenitor cell commitment during erythropoiesis. Cell Rep. 6, 231–244 (2014). · DOI
  25. Biegel, J. A. et al. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res. 59, 74–79 (1999).
  26. Varela, I. et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469, 539–542 (2011). · DOI
  27. Jones, S. et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330, 228–231 (2010). · DOI
  28. Pasqualucci, L. et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat. Genet. 43, 830–837 (2011). · DOI
  29. Beguelin, W. et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23, 677–692 (2013). · DOI
  30. Nikoloski, G. et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat. Genet. 42, 665–667 (2010). · DOI
  31. Stransky, N. et al. The mutational landscape of head and neck squamous cell carcinoma. Science 333, 1157–1160 (2011). · DOI
  32. Ntziachristos, P. et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat. Med. 18, 298–301 (2012). · DOI
  33. Hannum, G. et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. Mol. Cell 49, 359–367 (2013). · DOI · Paper page
  34. Simon, C. et al. A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. Genes Dev. 26, 651–656 (2012). · DOI · Paper page
  35. Wu, G. et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat. Genet. 44, 251–253 (2012). · DOI · Paper page
  36. Wang, G. G., Cai, L., Pasillas, M. P. & Kamps, M. P. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat. Cell Biol. 9, 804–812 (2007). · DOI
  37. Martinez-Garcia, E. et al. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood 117, 211–220 (2011). · DOI
  38. Jaffe, J. D. et al. Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nat. Genet. 45, 1386–1391 (2013). · DOI
  39. Hakimi, A. A. et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin. Cancer Res. 19, 3259–3267 (2013). · DOI
  40. Mar, B. G. et al. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat. Commun. 5, 3469 (2014). · DOI
  41. Rainier, S. et al. Relaxation of imprinted genes in human cancer. Nature 362, 747–749 (1993). This and the next paper represent the discovery of altered imprinting in cancer. · DOI
  42. Ogawa, O. et al. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature 362, 749–751 (1993). This and the previous paper represent the discovery of altered imprinting in cancer. · DOI
  43. Zhan, S., Shapiro, D. N. & Helman, L. J. Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J. Clin. Invest. 94, 445–448 (1994). · DOI
  44. Rainier, S., Dobry, C. J. & Feinberg, A. P. Loss of imprinting in hepatoblastoma. Cancer Res. 55, 1836–1838 (1995).
  45. Levine, A. J. et al. Genetic variation in insulin pathway genes and distal colorectal adenoma risk. Int. J. Colorectal Dis. 27, 1587–1595 (2012). · DOI
  46. Falls, J. G., Pulford, D. J., Wylie, A. A. & Jirtle, R. L. Genomic imprinting: implications for human disease. Am. J. Pathol. 154, 635–647 (1999). · DOI
  47. Hassan, A. B. & Howell, J. A. Insulin-like growth factor II supply modifies growth of intestinal adenoma in Apc(Min/+) mice. Cancer Res. 60, 1070–1076 (2000).
  48. Bjornsson, H. T. et al. Epigenetic specificity of loss of imprinting of the IGF2 gene in Wilms tumors. J. Natl Cancer Inst. 99, 1270–1273 (2007). · DOI
  49. Sakatani, T. et al. Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science 307, 1976–1978 (2005). · DOI
  50. DeBaun, M. R. et al. Epigenetic alterations of H19 and LIT1 distinguish patients with Beckwith-Wiedemann syndrome with cancer and birth defects. Am. J. Hum. Genet. 70, 604–611 (2002). This paper showed that epigenetic changes can precede and specifically confer risk of cancer, providing epigenetic epidemiological causal evidence similar to Li-Fraumeni and p53 mutations for genetic epidemiology. · DOI
  51. Ferron, S. R. et al. Differential genomic imprinting regulates paracrine and autocrine roles of IGF2 in mouse adult neurogenesis. Nat. Commun. 6, 8265 (2015). · DOI
  52. Ziegler, A. N. et al. IGF-II promotes stemness of neural restricted precursors. Stem Cells 30, 1265–1276 (2012). · DOI
  53. Wang, L. et al. Self-renewal of human embryonic stem cells requires insulin-like growth factor-1 receptor and ERBB2 receptor signaling. Blood 110, 4111–4119 (2007). · DOI
  54. Fischedick, G. et al. Nanog induces hyperplasia without initiating tumors. Stem Cell Res. 13, 300–315 (2014). · DOI
  55. Lengner, C. J. et al. Oct4 expression is not required for mouse somatic stem cell self-renewal. Cell Stem Cell 1, 403–415 (2007). · DOI
  56. Marucci, L. et al. Beta-catenin fluctuates in mouse ESCs and is essential for Nanog-mediated reprogramming of somatic cells to pluripotency. Cell Rep. 8, 1686–1696 (2014). · DOI
  57. Doi, A. et al. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat. Genet. 41, 1350–1353 (2009). · DOI
  58. Lu, X., Mazur, S. J., Lin, T., Appella, E. & Xu, Y. The pluripotency factor nanog promotes breast cancer tumorigenesis and metastasis. Oncogene 33, 2655–2664 (2014). · DOI
  59. Hochedlinger, K., Yamada, Y., Beard, C. & Jaenisch, R. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 121, 465–477 (2005). · DOI · Paper page
  60. Du, J., Johnson, L. M., Jacobsen, S. E. & Patel, D. J. DNA methylation pathways and their crosstalk with histone methylation. Nat. Rev. Mol. Cell Biol. 16, 519–532 (2015). · DOI · Paper page
  61. Wen, B., Wu, H., Shinkai, Y., Irizarry, R. A. & Feinberg, A. P. Large histone H3 lysine 9 dimethylated chromatin blocks distinguish differentiated from embryonic stem cells. Nat. Genet. 41, 246–250 (2009). This paper showed that large areas of heterochromatin expand during differentiation and can distinguish cell types. · DOI
  62. Tonge, P. D. et al. Divergent reprogramming routes lead to alternative stem-cell states. Nature 516, 192–197 (2014). · DOI
  63. Shakya, A. et al. Pluripotency transcription factor Oct4 mediates stepwise nucleosome demethylation and depletion. Mol. Cell. Biol. 35, 1014–1025 (2015). · DOI
  64. Gidekel, S., Pizov, G., Bergman, Y. & Pikarsky, E. Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell 4, 361–370 (2003). · DOI
  65. Lee, B. K. et al. Tgif1 counterbalances the activity of core pluripotency factors in mouse embryonic stem cells. Cell Rep. 13, 52–60 (2015). · DOI
  66. Rudin, C. M. et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat. Genet. 44, 1111–1116 (2012). · DOI
  67. Bass, A. J. et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat. Genet. 41, 1238–1242 (2009). · DOI
  68. Luo, W. et al. Embryonic stem cells markers SOX2, OCT4 and Nanog expression and their correlations with epithelial-mesenchymal transition in nasopharyngeal carcinoma. PLoS ONE 8, e56324 (2013). · DOI
  69. Chiou, S. H. et al. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res. 70, 10433–10444 (2010). · DOI
  70. Wang, D. et al. Oct-4 and Nanog promote the epithelial-mesenchymal transition of breast cancer stem cells and are associated with poor prognosis in breast cancer patients. Oncotarget 5, 10803–10815 (2014). · DOI
  71. Boyer, L. A. et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 122, 947–956 (2005). · DOI · Paper page
  72. Visvader, J. E. Cells of origin in cancer. Nature 469, 314–322 (2011). · DOI
  73. Friedmann-Morvinski, D. & Verma, I. M. Dedifferentiation and reprogramming: origins of cancer stem cells. EMBO Rep. 15, 244–253 (2014). · DOI
  74. Medema, J. P. Cancer stem cells: the challenges ahead. Nat. Cell Biol. 15, 338–344 (2013). · DOI
  75. Kai, K. et al. Maintenance of HCT116 colon cancer cell line conforms to a stochastic model but not a cancer stem cell model. Cancer Sci. 100, 2275–2282 (2009). · DOI
  76. Gupta, P. B. et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146, 633–644 (2011). · DOI · Paper page
  77. Schwitalla, S. et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 152, 25–38 (2013). · DOI
  78. Friedmann-Morvinski, D. et al. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science 338, 1080–1084 (2012). · DOI
  79. Barker, N. et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457, 608–611 (2009). · DOI
  80. Kikushige, Y. et al. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell 20, 246–259 (2011). · DOI
  81. Chen, W. J. et al. Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling. Nat. Commun. 5, 3472 (2014). · DOI
  82. Calabrese, C. et al. A perivascular niche for brain tumor stem cells. Cancer Cell 11, 69–82 (2007). · DOI
  83. Borovski, T. et al. Tumor microvasculature supports proliferation and expansion of glioma-propagating cells. Int. J. Cancer 125, 1222–1230 (2009). · DOI
  84. Vermeulen, L. et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 12, 468–476 (2010). · DOI · Paper page
  85. Badeaux, A. I. & Shi, Y. Emerging roles for chromatin as a signal integration and storage platform. Nat. Rev. Mol. Cell Biol. 14, 211–224 (2013). · DOI · Paper page
  86. Kolybaba, A. & Classen, A. K. Sensing cellular states – signaling to chromatin pathways targeting Polycomb and Trithorax group function. Cell Tissue Res. 356, 477–493 (2014). · DOI
  87. Wu, B. K. & Brenner, C. Suppression of TET1-dependent DNA demethylation is essential for KRAS-mediated transformation. Cell Rep. 9, 1827–1840 (2014). · DOI
  88. Gazin, C., Wajapeyee, N., Gobeil, S., Virbasius, C. M. & Green, M. R. An elaborate pathway required for Ras-mediated epigenetic silencing. Nature 449, 1073–1077 (2007). · DOI
  89. Wajapeyee, N., Malonia, S. K., Palakurthy, R. K. & Green, M. R. Oncogenic RAS directs silencing of tumor suppressor genes through ordered recruitment of transcriptional repressors. Genes Dev. 27, 2221–2226 (2013). · DOI
  90. Serra, R. W., Fang, M., Park, S. M., Hutchinson, L. & Green, M. R. A KRAS-directed transcriptional silencing pathway that mediates the CpG island methylator phenotype. eLife 3, e02313 (2014). · DOI
  91. Li, H. et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 460, 1136–1139 (2009). · DOI · Paper page
  92. Nguyen, L. V. et al. Barcoding reveals complex clonal dynamics of de novo transformed human mammary cells. Nature 528, 267–271 (2015). This paper describes the development of phenotypically heterogeneous, serially transplantable tumours from basal cells and luminal progenitors transduced with oncogenic KRAS. · DOI
  93. Trosko, J. E. & Tai, M. H. Adult stem cell theory of the multi-stage, multi-mechanism theory of carcinogenesis: role of inflammation on the promotion of initiated stem cells. Contrib. Microbiol. 13, 45–65 (2006). · DOI
  94. Suman, S. et al. Current perspectives of molecular pathways involved in chronic Inflammation-mediated breast cancer. Biochem. Biophys. Res. Commun. http://dx.doi.org/10.1016/j.bbrc.2015.10.133 (2015). · DOI
  95. Barham, W. et al. Aberrant activation of NF-κB signaling in mammary epithelium leads to abnormal growth and ductal carcinoma in situ. BMC Cancer 15, 647 (2015). · DOI
  96. Iliopoulos, D., Hirsch, H. A. & Struhl, K. An epigenetic switch involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 139, 693–706 (2009). · DOI · Paper page
  97. Do, D. V. et al. A genetic and developmental pathway from STAT3 to the OCT4-NANOG circuit is essential for maintenance of ICM lineages in vivo. Genes Dev. 27, 1378–1390 (2013). · DOI
  98. Tyagi, N. et al. p-21 activated kinase 4 (PAK4) maintains stem cell-like phenotypes in pancreatic cancer cells through activation of STAT3 signaling. Cancer Lett. 370, 260–267 (2016). · DOI
  99. Abu-Remaileh, M. et al. Chronic inflammation induces a novel epigenetic program that is conserved in intestinal adenomas and in colorectal cancer. Cancer Res. 75, 2120–2130 (2015). · DOI
  100. Lee, J. et al. Activation of innate immunity is required for efficient nuclear reprogramming. Cell 151, 547–558 (2012). The paper showed that the activation of innate immunity enhances the reprogramming efficiency of Yamanaka factors. · DOI
  101. Taniguchi, K. et al. A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature 519, 57–62 (2015). · DOI · Paper page
  102. Strano, S. et al. The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA damage. Mol. Cell 18, 447–459 (2005). · DOI
  103. Bora-Singhal, N. et al. YAP1 regulates OCT4 activity and SOX2 expression to facilitate self-renewal and vascular mimicry of stem-like cells. Stem Cells 33, 1705–1718 (2015). · DOI
  104. Zhu, J. et al. Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature 525, 206–211 (2015). · DOI · Paper page
  105. Pfister, N. T. et al. Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells. Genes Dev. 29, 1298–1315 (2015). · DOI
  106. Rai, K. et al. DNA demethylase activity maintains intestinal cells in an undifferentiated state following loss of APC. Cell 142, 930–942 (2010). · DOI
  107. Heyn, H. et al. Distinct DNA methylomes of newborns and centenarians. Proc. Natl Acad. Sci. USA 109, 10522–10527 (2012). · DOI · Paper page
  108. Florath, I., Butterbach, K., Muller, H., Bewerunge-Hudler, M. & Brenner, H. Cross-sectional and longitudinal changes in DNA methylation with age: an epigenome-wide analysis revealing over 60 novel age-associated CpG sites. Hum. Mol. Genet. 23, 1186–1201 (2014). · DOI
  109. Teschendorff, A. E., West, J. & Beck, S. Age-associated epigenetic drift: implications, and a case of epigenetic thrift? Hum. Mol. Genet. 22, R7–R15 (2013). The authors intriguingly argue that epigenetic drift has an evolutionary advantage. · DOI
  110. Sun, D. et al. Epigenomic profiling of young and aged HSCs reveals concerted changes during aging that reinforce self-renewal. Cell Stem Cell 14, 673–688 (2014). · DOI · Paper page
  111. Benayoun, B. A., Pollina, E. A. & Brunet, A. Epigenetic regulation of ageing: linking environmental inputs to genomic stability. Nat. Rev. Mol. Cell Biol. 16, 593–610 (2015). · DOI · Paper page
  112. McCord, R. P. et al. Correlated alterations in genome organization, histone methylation, and DNA-lamin A/C interactions in Hutchinson-Gilford progeria syndrome. Genome Res. 23, 260–269 (2013). · DOI
  113. Mihaylova, M. M. et al. Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis. Cell 145, 607–621 (2011). · DOI · Paper page
  114. Bungard, D. et al. Signaling kinase AMPK activates stress-promoted transcription via histone H2B phosphorylation. Science 329, 1201–1205 (2010). · DOI
  115. Wilson, M. J., Shivapurkar, N. & Poirier, L. A. Hypomethylation of hepatic nuclear DNA in rats fed with a carcinogenic methyl-deficient diet. Biochem. J. 218, 987–990 (1984). · DOI
  116. Ghoshal, A. K. & Farber, E. The induction of liver cancer by dietary deficiency of choline and methionine without added carcinogens. Carcinogenesis 5, 1367–1370 (1984). · DOI
  117. Bhave, M. R., Wilson, M. J. & Poirier, L. A. c-H-ras and c-K-ras gene hypomethylation in the livers and hepatomas of rats fed methyl-deficient, amino acid-defined diets. Carcinogenesis 9, 343–348 (1988). · DOI
  118. Pogribny, I. P. et al. Breaks in genomic DNA and within the p53 gene are associated with hypomethylation in livers of folate/methyl-deficient rats. Cancer Res. 55, 1894–1901 (1995).
  119. Giovannucci, E. et al. Folate, methionine, and alcohol intake and risk of colorectal adenoma. J. Natl Cancer Inst. 85, 875–884 (1993). · DOI
  120. Ciappio, E. D., Mason, J. B. & Crott, J. W. Maternal one-carbon nutrient intake and cancer risk in offspring. Nutr. Rev. 69, 561–571 (2011). · DOI
  121. Choi, S. W. et al. Chronic alcohol consumption induces genomic but not p53-specific DNA hypomethylation in rat colon. J. Nutr. 129, 1945–1950 (1999). · DOI
  122. van Engeland, M. et al. Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. Cancer Res. 63, 3133–3137 (2003).
  123. Zochbauer-Muller, S. et al. Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers. Int. J. Cancer 107, 612–616 (2003). · DOI
  124. Russo, A. L. et al. Differential DNA hypermethylation of critical genes mediates the stage-specific tobacco smoke-induced neoplastic progression of lung cancer. Clin. Cancer Res. 11, 2466–2470 (2005). · DOI · Paper page
  125. Bollati, V. et al. Changes in DNA methylation patterns in subjects exposed to low-dose benzene. Cancer Res. 67, 876–880 (2007). · DOI
  126. Maekita, T. et al. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin. Cancer Res. 12, 989–995 (2006). · DOI
  127. Chan, A. O. et al. Eradication of Helicobacter pylori infection reverses E-cadherin promoter hypermethylation. Gut 55, 463–468 (2006). · DOI
  128. Christensen, B. C. et al. Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome. Cancer Res. 69, 227–234 (2009). · DOI
  129. Pujadas, E. & Feinberg, A. P. Regulated noise in the epigenetic landscape of development and disease. Cell 148, 1123–1131 (2012). · DOI
  130. Hansen, K. D. et al. Large-scale hypomethylated blocks associated with Epstein-Barr virus-induced B-cell immortalization. Genome Res. 24, 177–184 (2014). This paper showed the link between hypomethylated blocks, variable gene expression, and heterochromatin LOCKs/LADs in cancer. · DOI
  131. Meuleman, W. et al. Constitutive nuclear lamina-genome interactions are highly conserved and associated with A/T-rich sequence. Genome Res. 23, 270–280 (2013). · DOI · Paper page
  132. Banerji, C. R. et al. Cellular network entropy as the energy potential in Waddington's differentiation landscape. Sci. Rep. 3, 3039 (2013). · DOI
  133. Chen, X. et al. G9a/GLP-dependent histone H3K9me2 patterning during human hematopoietic stem cell lineage commitment. Genes Dev. 26, 2499–2511 (2012). · DOI
  134. Liu, N. et al. Recognition of H3K9 methylation by GLP is required for efficient establishment of H3K9 methylation, rapid target gene repression, and mouse viability. Genes Dev. 29, 379–393 (2015). · DOI
  135. Ahmed, K. et al. Global chromatin architecture reflects pluripotency and lineage commitment in the early mouse embryo. PLoS One 5, e10531 (2010). · DOI
  136. Therizols, P. et al. Chromatin decondensation is sufficient to alter nuclear organization in embryonic stem cells. Science 346, 1238–1242 (2014). · DOI
  137. Eskeland, R. et al. Ring1B compacts chromatin structure and represses gene expression independent of histone ubiquitination. Mol. Cell 38, 452–464 (2010). · DOI
  138. Vallot, C., Herault, A., Boyle, S., Bickmore, W. A. & Radvanyi, F. PRC2-independent chromatin compaction and transcriptional repression in cancer. Oncogene 34, 741–751 (2015). · DOI
  139. Lemaitre, C. & Bickmore, W. A. Chromatin at the nuclear periphery and the regulation of genome functions. Histochem. Cell Biol. 144, 111–122 (2015). · DOI
  140. Burke, B. & Stewart, C. L. The nuclear lamins: flexibility in function. Nat. Rev. Mol. Cell Biol. 14, 13–24 (2013). · DOI
  141. Shah, P. P. et al. Lamin B1 depletion in senescent cells triggers large-scale changes in gene expression and the chromatin landscape. Genes Dev. 27, 1787–1799 (2013). · DOI · Paper page
  142. Harr, J. C. et al. Directed targeting of chromatin to the nuclear lamina is mediated by chromatin state and A-type lamins. J. Cell Biol. 208, 33–52 (2015). · DOI
  143. Guarda, A., Bolognese, F., Bonapace, I. M. & Badaracco, G. Interaction between the inner nuclear membrane lamin B receptor and the heterochromatic methyl binding protein, MeCP2. Exp. Cell Res. 315, 1895–1903 (2009). · DOI
  144. Schooley, A., Moreno-Andres, D., De Magistris, P., Vollmer, B. & Antonin, W. The lysine demethylase LSD1 is required for nuclear envelope formation at the end of mitosis. J. Cell Sci. 128, 3466–3477 (2015). · DOI
  145. Montes de Oca, R., Shoemaker, C. J., Gucek, M., Cole, R. N. & Wilson, K. L. Barrier-to-autointegration factor proteome reveals chromatin-regulatory partners. PLoS One 4, e7050 (2009). · DOI
  146. Demmerle, J., Koch, A. J. & Holaska, J. M. The nuclear envelope protein emerin binds directly to histone deacetylase 3 (HDAC3) and activates HDAC3 activity. J. Biol. Chem. 287, 22080–22088 (2012). · DOI
  147. Somech, R. et al. The nuclear-envelope protein and transcriptional repressor LAP2β interacts with HDAC3 at the nuclear periphery, and induces histone H4 deacetylation. J. Cell Sci. 118, 4017–4025 (2005). · DOI · Paper page
  148. Holaska, J. M. & Wilson, K. L. An emerin “proteome”: purification of distinct emerin-containing complexes from HeLa cells suggests molecular basis for diverse roles including gene regulation, mRNA splicing, signaling, mechanosensing, and nuclear architecture. Biochemistry 46, 8897–8908 (2007). · DOI
  149. Finlan, L. E. et al. Recruitment to the nuclear periphery can alter expression of genes in human cells. PLoS Genet. 4, e1000039 (2008). · DOI
  150. Melcer, S. et al. Histone modifications and lamin A regulate chromatin protein dynamics in early embryonic stem cell differentiation. Nat. Commun. 3, 910 (2012). · DOI
  151. Adamo, A. et al. LSD1 regulates the balance between self-renewal and differentiation in human embryonic stem cells. Nat. Cell Biol. 13, 652–659 (2011). · DOI
  152. Ma, D. K., Chiang, C. H., Ponnusamy, K., Ming, G. L. & Song, H. G9a and Jhdm2a regulate embryonic stem cell fusion-induced reprogramming of adult neural stem cells. Stem Cells 26, 2131–2141 (2008). · DOI
  153. Sadaie, M. et al. Redistribution of the Lamin B1 genomic binding profile affects rearrangement of heterochromatic domains and SAHF formation during senescence. Genes Dev. 27, 1800–1808 (2013). · DOI · Paper page
  154. Zane, L., Sharma, V. & Misteli, T. Common features of chromatin in aging and cancer: cause or coincidence? Trends Cell Biol. 24, 686–694 (2014). · DOI
  155. Shankar, S. R. et al. G9a, a multipotent regulator of gene expression. Epigenetics 8, 16–22 (2013). · DOI
  156. McDonald, O. G., Wu, H., Timp, W., Doi, A. & Feinberg, A. P. Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. Nat. Struct. Mol. Biol. 18, 867–874 (2011). · DOI
  157. Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704–715 (2008). · DOI
  158. Feinberg, A. P. & Irizarry, R. A. Evolution in health and medicine Sackler colloquium: stochastic epigenetic variation as a driving force of development, evolutionary adaptation, and disease. Proc. Natl Acad. Sci. USA 107 (Suppl. 1), 1757–1764 (2010). · DOI
  159. Timp, W. & Feinberg, A. P. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat. Rev. Cancer 13, 497–510 (2013). · DOI
  160. Ohlsson, R. et al. Epigenetic variability and the evolution of human cancer. Adv. Cancer Res. 88, 145–168 (2003). · DOI
  161. Hansen, K. D. et al. Increased methylation variation in epigenetic domains across cancer types. Nat. Genet. 43, 768–775 (2011). · DOI
  162. Timp, W. et al. Large hypomethylated blocks as a universal defining epigenetic alteration in human solid tumors. Genome Med. 6, 61 (2014). · DOI
  163. Berman, B. P. et al. Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nat. Genet. 44, 40–46 (2012). · DOI · Paper page
  164. Teschendorff, A. E. et al. Epigenetic variability in cells of normal cytology is associated with the risk of future morphological transformation. Genome Med. 4, 24 (2012). This paper showed that epigenetic variability in normal tissue predicts the development of later cancers. · DOI
  165. Teschendorff, A. E. & Widschwendter, M. Differential variability improves the identification of cancer risk markers in DNA methylation studies profiling precursor cancer lesions. Bioinformatics 28, 1487–1494 (2012). · DOI
  166. Dinalankara, W. & Bravo, H. C. Gene expression signatures based on variability can robustly predict tumor progression and prognosis. Cancer Inform. 14, 71–81 (2015). · DOI
  167. Vandiver, A. R. et al. Age and sun exposure-related widespread genomic blocks of hypomethylation in nonmalignant skin. Genome Biol. 16, 80 (2015). · DOI
  168. Teschendorff, A. E., Banerji, C. R., Severini, S., Kuehn, R. & Sollich, P. Increased signaling entropy in cancer requires the scale-free property of protein interaction networks. Sci. Rep. 5, 9646 (2015). · DOI
  169. Singer, Z. S. et al. Dynamic heterogeneity and DNA methylation in embryonic stem cells. Mol. Cell 55, 319–331 (2014). · DOI
  170. Reddy, K. L. & Feinberg, A. P. Higher order chromatin organization in cancer. Semin. Cancer Biol. 23, 109–115 (2013). · DOI
  171. Carone, D. M. & Lawrence, J. B. Heterochromatin instability in cancer: from the Barr body to satellites and the nuclear periphery. Semin. Cancer Biol. 23, 99–108 (2013). · DOI
  172. Kind, J. et al. Single-cell dynamics of genome-nuclear lamina interactions. Cell 153, 178–192 (2013). · DOI
  173. Schlimgen, R. J., Reddy, K. L., Singh, H. & Krangel, M. S. Initiation of allelic exclusion by stochastic interaction of Tcrb alleles with repressive nuclear compartments. Nat. Immunol. 9, 802–809 (2008). · DOI
  174. Zhao, H. et al. PARP1- and CTCF-mediated interactions between active and repressed chromatin at the lamina promote oscillating transcription. Mol. Cell 59, 984–997 (2015). · DOI
  175. Wassef, M. et al. Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesis. Genes Dev. 29, 2547–2562 (2015). · DOI
  176. Guelen, L. et al. Domain organization of human chromosomes revealed by mapping of nuclear lamina interactions. Nature 453, 948–951 (2008). · DOI
  177. Boros, J., Arnoult, N., Stroobant, V., Collet, J. F. & Decottignies, A. Polycomb repressive complex 2 and H3K27me3 cooperate with H3K9 methylation to maintain heterochromatin protein 1alpha at chromatin. Mol. Cell. Biol. 34, 3662–3674 (2014). · DOI
  178. Hnisz, D. et al. Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers. Mol. Cell 58, 362–370 (2015). The paper showed that super-enhancers integrate developmental cues and oncogenic signalling pathways to regulate genes that control cell identity or tumour development. · DOI · Paper page
  179. Bahar Halpern, K. et al. Bursty gene expression in the intact mammalian liver. Mol. Cell 58, 147–156 (2015). · DOI
  180. Lam, A. & Deans, T. L. A noisy tug of war: the battle between transcript production and degradation in the liver. Dev. Cell 33, 3–4 (2015). · DOI
  181. Li, G. et al. Extensive promoter-centered chromatin interactions provide a topological basis for transcription regulation. Cell 148, 84–98 (2012). · DOI · Paper page
  182. Noordermeer, D. et al. Variegated gene expression caused by cell-specific long-range DNA interactions. Nat. Cell Biol. 13, 944–951 (2011). · DOI
  183. Whyte, W. A. et al. Enhancer decommissioning by LSD1 during embryonic stem cell differentiation. Nature 482, 221–225 (2012). · DOI · Paper page
  184. Dey, A., Nishiyama, A., Karpova, T., McNally, J. & Ozato, K. Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription. Mol. Biol. Cell 20, 4899–4909 (2009). · DOI
  185. Adam, R. C. et al. Pioneer factors govern super-enhancer dynamics in stem cell plasticity and lineage choice. Nature 521, 366–370 (2015). This paper showed that the microenvironment dynamically reprogrammes the location of super-enhancers in follicular stem cells. · DOI
  186. Gomez-Diaz, E. & Corces, V. G. Architectural proteins: regulators of 3D genome organization in cell fate. Trends Cell Biol. 24, 703–711 (2014). · DOI
  187. Kanduri, C. et al. Functional association of CTCF with the insulator upstream of the H19 gene is parent of origin-specific and methylation-sensitive. Curr. Biol. 10, 853–856 (2000). · DOI · Paper page
  188. Gerlinger, M. et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46, 225–233 (2014). This paper used multi-region sequencing to analyse tumour evolution in renal cell carcinoma and reported distinct, spatially separated mutations converging on modifiers of specific histone marks. · DOI
  189. Yildirim, E., Sadreyev, R. I., Pinter, S. F. & Lee, J. T. X-chromosome hyperactivation in mammals via nonlinear relationships between chromatin states and transcription. Nat. Struct. Mol. Biol. 19, 56–61 (2012). · DOI
  190. Stephens, A. D. et al. Pericentric chromatin loops function as a nonlinear spring in mitotic force balance. J. Cell Biol. 200, 757–772 (2013). · DOI
  191. Pang, B., de Jong, J., Qiao, X., Wessels, L. F. & Neefjes, J. Chemical profiling of the genome with anti-cancer drugs defines target specificities. Nat. Chem. Biol. 11, 472–480 (2015). · DOI
  192. Cheng, J. et al. Tryptophan derivatives regulate the transcription of Oct4 in stem-like cancer cells. Nat. Commun. 6, 7209 (2015). · DOI
  193. Love, C. et al. The genetic landscape of mutations in Burkitt lymphoma. Nat. Genet. 44, 1321–1325 (2012). · DOI
  194. Robinson, G. et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 488, 43–48 (2012). · DOI
  195. Fujimoto, A. et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat. Genet. 44, 760–764 (2012). · DOI
  196. Li, M. et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat. Genet. 43, 828–829 (2011). · DOI
  197. Stephens, P. J. et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 486, 400–404 (2012). · DOI
  198. Smith, M. J. et al. Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. Nat. Genet. 45, 295–298 (2013). · DOI
  199. Jiao, Y. et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331, 1199–1203 (2011). · DOI
  200. Kolla, V., Zhuang, T., Higashi, M., Naraparaju, K. & Brodeur, G. M. Role of CHD5 in human cancers: 10 years later. Cancer Res. 74, 652–658 (2014). · DOI

200 of 233 shown

Cited by

Sorted by citations

Metadata

Authors
Feinberg, A. P., Koldobskiy, M. A., & Göndör, A.
Venue
Nature Reviews Genetics
Publisher
Springer Science and Business Media LLC
Published
2016-03-14
Volume
17
Issue
5
Pages
284-299
ISSN
  • 1471-0056
  • 1471-0064
DOI
10.1038/nrg.2016.13
PMC
PMC4888057
Cited by
841
References
41
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review